Share Price | Organon & Co. Stock Analysis & Recommendation

Q: What does Organon & Co. do?

Overview: Organon & Co. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.Financial Snapshot: Most recent Net Sales: 1,513 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 87 Million (Quarterly Results - Mar 2025) Market-cap: USD 2,560.57 Million (Small Cap)Key Metrics: P/E: 3.00 Dividend Yield: 0.20% Debt Equity: 15.51 Return on Equity: 163.16% Price to Book: 4.72 Contact Details: Registrar Address: Not available.

Q: Is Organon & Co. overvalued or undervalued?

As of 2 May 2024, the valuation grade for Organon & Co. moved from risky to very attractive, indicating a significant improvement in its investment appeal. The company appears undervalued, supported by a P/E ratio of 3, an EV to EBITDA ratio of 6.41, and a Price to Book Value of 4.59. In comparison, Exelixis, Inc. has a P/E ratio of 15.81 and an EV to EBITDA of 11.97, while Alkermes Plc shows a P/E of 13.77 and an EV to EBITDA of 9.41, highlighting Organon’s relative undervaluation within the industry.Despite recent struggles, with a year-to-date return of -27.28% compared to the S&P 500's 12.22%, the substantial drop in Organon's stock price may present a buying opportunity given its attractive valuation metrics.

Q: Is Organon & Co. technically bullish or bearish?

As of 19 September 2025, the technical trend for Organon & Co. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a mildly bearish trend, alongside the monthly MACD and KST both showing bearish signals. The weekly Bollinger Bands are bullish, but this is offset by the overall bearish indicators on the monthly timeframe. In terms of performance, Organon has underperformed the S&P 500 significantly over the year, with a return of -45.77% compared to the S&P 500's 16.64%.

Results Declared: Organon & Co. has declared results on 11 Feb 2026! Click here to unlock the latest financial performance

Mojo Score Change: Organon & Co. has changed its score on 11 Feb 2026. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.62 M

Shareholding (Dec 2025)

FII

10.20%

Held by 216 FIIs

DII

44.62%

Held by 72 DIIs

Promoter

0.02%

How big is Organon & Co.?

22-Jun-2025

As of Jun 18, Organon & Co. has a market capitalization of 2,560.57 million, with net sales of 6,294.00 million and a net profit of 750.00 million over the latest four quarters.

View full answer

What does Organon & Co. do?

22-Jun-2025

Organon & Co. is a small-cap pharmaceutical and biotechnology company with recent net sales of $1.513 billion and a net profit of $87 million. Key metrics include a P/E ratio of 3.00, a dividend yield of 0.20%, and a market cap of $2.56 billion.

View full answer

Is Organon & Co. overvalued or undervalued?

20-Sep-2025

As of May 2, 2024, Organon & Co. is considered very attractive for investment due to its undervaluation, reflected in a P/E ratio of 3 and an EV to EBITDA ratio of 6.41, despite a year-to-date return of -27.28%.

View full answer

Is Organon & Co. technically bullish or bearish?

23-Sep-2025

As of September 19, 2025, Organon & Co. is in a mildly bearish trend, indicated by daily moving averages and bearish signals from the monthly MACD and KST, while underperforming the S&P 500 with a return of -45.77% compared to its 16.64%.

View full answer

Compare Organon & Co. with Similar Stocks

Apellis Pharmaceuticals, Inc.Alkermes Plc Intra-Cellular Therapies, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Company has a low Debt to Equity ratio (avg) at times

Healthy long term growth as Net Sales has grown by an annual rate of 13.72% and Operating profit at -3.44%

Negative results in Jun 25

With ROE of 163.16%, it has a very attractive valuation with a 4.59 Price to Book Value

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,106 Million (Small Cap)

P/E

3.00

Industry P/E

Dividend Yield

0.73%

Debt Equity

8,066.00

Return on Equity

0.00%

Price to Book

0.00

Revenue and Profits:

Net Sales:

1,507 Million

(Quarterly Results - Dec 2025)

Net Profit:

-205 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

-17.11%

1 Year

-53.44%

2 Years

-59.41%

3 Years

-70.65%

4 Years

-80.01%

5 Years

0.0%

Organon & Co. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-5.15%

EBIT Growth (5y)

-15.13%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

3.73

Net Debt to Equity (avg)

15.51

Sales to Capital Employed (avg)

0.70

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

47.22%

Pledged Shares

Institutional Holding

91.22%

ROCE (avg)

25.39%

ROE (avg)

858.56%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.28

EV to EBIT

7.95

EV to EBITDA

6.43

EV to Capital Employed

1.18

EV to Sales

1.70

PEG Ratio

Dividend Yield

0.43%

ROCE (Latest)

14.89%

ROE (Latest)

111.78%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 96 Schemes (45.06%)

Foreign Institutions

Held by 216 Foreign Institutions (10.2%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -5.93% vs 0.50% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -228.12% vs 10.34% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,507.00",
          "val2": "1,602.00",
          "chgp": "-5.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "306.00",
          "val2": "450.00",
          "chgp": "-32.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "121.00",
          "val2": "131.00",
          "chgp": "-7.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-308.00",
          "val2": "-4.00",
          "chgp": "-7,600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-205.00",
          "val2": "160.00",
          "chgp": "-228.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "144.00%",
          "val2": "223.50%",
          "chgp": "-7.95%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -2.92% vs 2.24% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -78.36% vs -15.54% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,216.00",
          "val2": "6,403.00",
          "chgp": "-2.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,566.00",
          "val2": "1,775.00",
          "chgp": "-11.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "504.00",
          "val2": "529.00",
          "chgp": "-4.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-396.00",
          "val2": "-93.00",
          "chgp": "-325.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "187.00",
          "val2": "864.00",
          "chgp": "-78.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "196.30%",
          "val2": "234.00%",
          "chgp": "-3.77%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

1,507.00

1,602.00

-5.93%

Operating Profit (PBDIT) excl Other Income

306.00

450.00

-32.00%

Interest

121.00

131.00

-7.63%

Exceptional Items

-308.00

-4.00

-7,600.00%

Consolidate Net Profit

-205.00

160.00

-228.12%

Operating Profit Margin (Excl OI)

144.00%

223.50%

-7.95%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -5.93% vs 0.50% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -228.12% vs 10.34% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

6,216.00

6,403.00

-2.92%

Operating Profit (PBDIT) excl Other Income

1,566.00

1,775.00

-11.77%

Interest

504.00

529.00

-4.73%

Exceptional Items

-396.00

-93.00

-325.81%

Consolidate Net Profit

187.00

864.00

-78.36%

Operating Profit Margin (Excl OI)

196.30%

234.00%

-3.77%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -2.92% vs 2.24% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -78.36% vs -15.54% in Dec 2024

All Annual Results

Company CV

About Organon & Co.

Organon & Co.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available